Novo Nordisk A/S (Novo Nordisk A/S) Other Long-Term Liabilities

: $1,000 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S's other long-term liabilities for the quarter that ended in Dec. 2023 was $1,000 Mil.

Novo Nordisk A/S's quarterly other long-term liabilities increased from Jun. 2023 ($862 Mil) to Sep. 2023 ($878 Mil) and increased from Sep. 2023 ($878 Mil) to Dec. 2023 ($1,000 Mil).

Novo Nordisk A/S's annual other long-term liabilities declined from Dec. 2021 ($719 Mil) to Dec. 2022 ($668 Mil) but then increased from Dec. 2022 ($668 Mil) to Dec. 2023 ($1,000 Mil).

Novo Nordisk A/S Other Long-Term Liabilities Historical Data

The historical data trend for Novo Nordisk A/S's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities																-	-	-	-	-

Novo Nordisk A/S Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Novo Nordisk A/S Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.